Mechanistic investigations into the species differences in pinometostat clearance: impact of binding to alpha-1-acid glycoprotein and permeability-limited hepatic uptake

References

• Azuma M, Nishioka Y, Aono Y, et al. (2007). Role of α1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Amer J Resp Crit Care Med 176:1243–50
   PubMed Web of Science ®Google Scholar
• Basavapathruni A, Olhava EJ, Daigle SR, et al. (2014). Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharm Drug Dispos 35:237–52
   PubMed Web of Science ®Google Scholar
• Belpaire FM, DeRick A, Dello C, et al. (1987). α1-acid glycoprotein and serum binding in healthy and diseased dogs. J Vet Pharmacol Ther 10:43–8
   PubMed Web of Science ®Google Scholar
• Bernt KM, Zhu N, Sinha AU, et al. (2011). MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20:66–78
   PubMed Web of Science ®Google Scholar
• Biswas D, Milne TA, Basrur V, et al. (2011). Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci Unit States Am 108:15751–6
   PubMed Web of Science ®Google Scholar
• Bowen RAR, Remaley AT. (2014). Interferences from blood collection tube components on clinical chemistry assays. Biochem Med 24:31–44
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmaco and Biopharm 10:201–27
   PubMedGoogle Scholar
• Butler P, Frost K, Barnes K, et al. (2015). Impact of blood collection method on human plasma protein binding for compounds preferentially binding to α1-acid glycoprotein. Poster presented at the ISSX 20th North American meeting; 2015 Oct 18–22; Orlando, FL, USA
   Google Scholar
• Chauvelot-Moachon L, Delers F, Pous F, et al. (1988). Alpha-1-acid glycoprotein concentrations and protein binding of propranolol in Sprague-Dawley and Dark Agouti rat strains treated by phenobarbital. J Pharmacol Exp Ther 244:1103–8
   PubMed Web of Science ®Google Scholar
• Chesworth R, Olhava EJ, Kuntz KW, et al. (2013). From protein to candidate: discovery of EPZ-5676, a potent and selective inhibitor of the histone methyltransferase DOT1L. Abstracts of Papers, 246th ACS National Meeting & Exposition; 2013 Sept 8–12; Indianapolis, IN, United States
   Google Scholar
• Daigle SR, Olhava EJ, Therkelsen CA, et al. (2013). Potent inhibition of DOT1L as treatment for MLL-fusion leukemia. Blood 122:1017–25
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Dello CP, Belpaire FM, Kint JA, Freyman NH. (1987). Dog alpha-1-acid glycoprotein: purification and biochemical characterization. J Pharmacol Met 18:335–45
   PubMedGoogle Scholar
• Devine JE. (1984). Drug-protein binding interferences caused by the plasticizer TBEP. Clin Biochem 17:345–7
   PubMed Web of Science ®Google Scholar
• Fournier T, Medjoubi NN, Porquet D. (2000). Alpha-1-acid glycoprotein. Biochim Biophys Acta 1482:157–71
   PubMed Web of Science ®Google Scholar
• Gianetti AM, Wong H, Dijkgraaf GJP, et al. (2011). Identification, characterization, and implications of species-dependent plasma protein binding of the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem 54:2592–601
   PubMed Web of Science ®Google Scholar
• Graham RA, Lum B, Cheeti S, et al. (2011). Pharmacokinetics of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 17:2512–20
   PubMed Web of Science ®Google Scholar
• Graham RA, Hop CE, Borin MT, et al. (2012). Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol 74:788–96
   PubMed Web of Science ®Google Scholar
• Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–79
   PubMed Web of Science ®Google Scholar
• Jones HM, Barton HA, Lai Y, et al. (2012). Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007–17
   PubMed Web of Science ®Google Scholar
• Jones RD, Jones HM, Rowland M, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, Part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 100:4074–89
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters Nigel J, Argikar Upendra A, et al. (2013a). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. J Clin Pharmacol 53:178–91
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters Nigel J, Argikar Upendra A, et al. (2013b). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. J Clin Pharmacol 53:167–77
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2007). Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 59:1177–92
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2006). Prediction of human drug clearance from animal data: application of the rule of exponents and ‘fu corrected intercept method’ (FCIM). J Pharm Sci 95:1810–21
   PubMed Web of Science ®Google Scholar
• Mahmood I. (2000). Interspecies scaling: role of protein binding in the prediction of clearance from animals to humans. J Clin Pharmacol 40:1439–46
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–95
   PubMed Web of Science ®Google Scholar
• Mahmood I, Boxenbaum H. (2014). Vertical allometry: fact or fiction? Reg Toxicol Pharmacol 68:468–74
   PubMed Web of Science ®Google Scholar
• Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Disp 27:1350–9
   PubMed Web of Science ®Google Scholar
• Paine SW, Parker AJ, Gardiner P, et al. (2008). Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 36:1365–74
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. (1977). Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmaco Biopharm 5:625–53
   PubMedGoogle Scholar
• Putnam FW. (1984). Progress in plasma proteins. In: The plasma proteins, Vol. IV, structure, function and genetic control. Orlando, FL: Academic Press, 1–44
   Google Scholar
• Rikihisa Y, Yamamoto S, Kwak I, et al. (1994). C-reactive protein and α-1-acid glycoprotein levels in dogs infected with Ehrlichia canis. J Clin Microbio 32:912–7
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci 100:4090–110
   PubMed Web of Science ®Google Scholar
• Rioux N, Waters NJ. (2016). Physiologically-based pharmacokinetic modeling in pediatric oncology drug development. Drug Metab Dispos. DOI: 10.1124/dmd.115.068031
   PubMed Web of Science ®Google Scholar
• Sager G, Little C. (1989). The effect of the plasticizers TBEP (tris-(2-butoxyethyl)-phosphate) and DEHP (di-(2-ethylhexyl)-phthalate) on beta-adrenergic ligand binding to alpha 1-acid glycoprotein and mononuclear leukocytes. Biochem Pharmacol 38:2551–7
   PubMed Web of Science ®Google Scholar
• Shah VP, Knapp G, Skelly JP, Cabana BE. (1982). Interference with measurements of certain drugs in plasma by a plasticizer in vacutainer tubes. Clin Chem 28:2327–8
   PubMed Web of Science ®Google Scholar
• Stein E, Garcia-Manero G, Rizzieri D, et al. (2014). The DOT1L inhibitor EPZ-5676: Safety and activity in relapsed/refractory patients with MLL-rearranged leukemia. Blood 124:387
   Google Scholar
• Stolina M, Schett G, Dwyer D, et al. (2009). RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparsion with anti-TNFα or anti-IL-1 therapies. Arthritis Res Ther 11:R187
   PubMed Web of Science ®Google Scholar
• Tang H, Hussain A, Leal M, et al. (2007). Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886–93
   PubMed Web of Science ®Google Scholar
• Tang H, Mayersohn M. (2006). A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 95:1783–99
   PubMed Web of Science ®Google Scholar
• Tang H, Mayersohn M. (2005). A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Disp 33:1297–303
   PubMed Web of Science ®Google Scholar
• Wajima T, Fukumura K, Yano Y, Oguma T. (2002). Prediction of human clearance from animal data and molecular structural parameters using multivariate regression analysis. J Pharm Sci 91:2489–99
   PubMed Web of Science ®Google Scholar
• Waters NJ, Thomson B, Gardner I, et al. (2014). Pediatric dose determinations for the phase I study of the DOT1L inhibitor, EPZ-5676, in MLL-r acute leukemia: leveraging early clinical data in adults through physiologically-based pharmacokinetic modeling. Blood 124:3619
   Web of Science ®Google Scholar
• Waters NJ, Smith SA, Olhava EJ, et al. (2016). Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human. Cancer Chemother Pharmacol 77:43–62
   PubMed Web of Science ®Google Scholar
• Webborn PJ, Parker AJ, Denton RL, Riley RJ. (2007). In vitro-in vivo extrapolation of hepatic clearance involving active uptake: theoretical and experimental aspects. Xenobiotica 37:1090–109
   PubMed Web of Science ®Google Scholar
• Wright JD, Boudinot FD, Ujhelyi MR. (1996). Measurement and analysis of unbound drug concentrations. Clin. Pharmacokinetics 30:445–62
   PubMed Web of Science ®Google Scholar